Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQA3810 + nucleos(t)ide analogue
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TQA3810 + NUC is a combination therapy under investigation for the treatment of chronic hepatitis B (CHB). TQA3810 is an orally administered, potent, and selective Toll-like receptor 8 (TLR8) agonist developed by Chia Tai Tianqing Pharmaceutical Group. By activating TLR8 in myeloid cells, TQA3810 induces the secretion of cytokines like IL-12 and TNF-α, which are intended to stimulate the innate immune system and restore HBV-specific adaptive immune responses. The combination includes a nucleos(t)ide analogue (NUC), such as entecavir or tenofovir, which acts as a reverse transcriptase inhibitor to suppress viral replication. This dual approach aims to achieve a functional cure for CHB by combining potent viral suppression with immune stimulation.
- Other names
- TQA3810 + NUCTQA3810 plus nucleos(t)ide analogue
02
Targets
TLR8 (Toll-like receptor 8)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on TQA3810 + nucleos(t)ide analogue.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQA3810 + nucleos(t)ide analogue.